6533b81ffe1ef96bd1279086
RESEARCH PRODUCT
Antioxidative component of docosahexaenoic acid in the brain in diabetes
Emma ArnalFrancisco J. RomeroFrancisco J. RomeroSiv Johnsen-sorianoDaniel López-maloMaría Mirandasubject
BioquímicaBiología molecularChemistryDiabetesEnfermedad cardiovascularCellNeurotoxicityPharmacologymedicine.diseaseBrain CellNeuroprotectionmedicine.anatomical_structureDocosahexaenoic acidDiabetes mellitusGene expressionmedicineNeuroprostanesdescription
The mechanisms underlying diabetic encephalopathy are only partially understood. This chapter tries to address the mechanisms of diabetes-induced cell and tissue damage in the brain, and discusses whether docosahexaenoic acid (DHA) could attenuate the degenerative changes observed in the diabetic brain. DHA is involved in brain and retina physiological functions, aging, and neurological and behavioral illnesses. There are a large number of bioactive metabolites of DHA, namely, maresins, protectins, resolvins, electrophilic oxo-derivatives, epoxides, neuroprostanes, neuroketals, and different DHA conjugates. Among them stands out Neuroprotectin D1 (NPD1), the first identified stereoselective bioactive product of DHA, NDP1 exerts neuroprotection in models of experimental diabetes. Overall, NPD1 promotes brain cell survival via the induction of antiapoptotic and neuroprotective gene expression programs that suppress neurotoxicity. Thus NPD1 elicits potent cell-protective, antiinflammatory, prosurvival, and repair signaling. Recent research has put forward the neuroprotective effects of docosanoids and the recently introduced elovanoids (DHA-elongated 32- or 34-carbon fatty acids by the action of elongation of very long chain fatty acids-4—ELOVL4). Sin financiación No data JCR 2019 No data SJR 2019 No data IDR 2019 UEV
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-01-01 |